{"Clinical Trial ID": "NCT00593827", "Intervention": ["INTERVENTION 1:", "Ixabepilone 16 mg/m^2", "ixabepilone 16 mg/m^2 per week for 3 weeks followed by a week of rest", "INTERVENTION 2:", "Ixabepilone 40 mg/m^2", "ixabepilone 40 mg/m^2 every 3 weeks"], "Eligibility": ["Incorporation criteria:", "A BCM that can be measured by RECIST or has a non-measurable disease with CA27.29 (or CA15.3) 50", "Does the human epidermal growth factor Receptor 2 (HER2) have negative breast cancer?", "Prior chemotherapy is allowed without limitation of the number of prior treatments.", "Two or more weeks have elapsed since the last treatment with chemotherapy or radiotherapy", "Has a performance status (PS) of the Eastern Cooperative Oncology Group (ECOG) of 0-2", "Is female, 18 years old", "The protocol defined the appropriate laboratory values", "Negative pregnancy test within 7 calendar days prior to registration", "Signed informed consent of patient", "- Exclusion criteria:", "Previous treatment with ixabepilone or other epothilone", "To HER2+ disease", "(National Cancer Institute Common Terminology Criteria Effective Events [NCI CTCAE] Grade 3-4) History of hypersensitivity reaction to a medicine formulated in Cremophor \u00ae EL (polyoxyethyl castor oil)", "\u2022 Receives simultaneous immunotherapy, hormone therapy or radiotherapy", "\u2022 Receives or has received concomitant experimental treatment within the last 30 days", "In peripheral neuropathy > Grade 1", "Participants with stable brain metastases that are non-steroidal at least 2 weeks are eligible", "Is pregnant or breast-feeding"], "Results": ["Performance measures:", "6-month progression-free survival rate (FSP) 6-month progression-free survival rate (FSP) 6-month progression-free survival rate (FSP) 6-month progression-free survival rate (FSP) 6-month progression-free survival rate (FSP) 6-month progression-free survival rate (FSP) 6-month progression-free survival rate (FSP) 6-month progression-free survival rate (FSP) 6-month progression-free survival rate (FSP)", "The 6-month SFP was defined as the proportion of participants who did not progress or died within 6 months.", "Time limit: From date of randomization to 6 months of study", "Results 1:", "Title of the arm/group: Ixabepilone 16 mg/m^2", "Description of the arm/group: ixabepilone 16 mg/m^2 per week for 3 weeks followed by a week of rest", "Total number of participants analysed: 85", "Type of measurement: Number", "Unit of measure: Percentage of participants 28.6 (18.9 to 38.9)", "Results 2:", "Title of the arm/group: Ixabepilone 40 mg/m^2", "Description of the arm/group: ixabepilone 40 mg/m^2 every 3 weeks", "Total number of participants analysed: 91", "Type of measurement: Number", "Unit of measure: Percentage of participants 42.7 (31.5 to 53.5)"], "Adverse Events": ["Undesirable Events 1:", "Total: 25/82 (30.49%)", "Neutropenia 1/82 (1.22%)", "Anemia 1/82 (1.22%)", "Thrombocytopenia 1/82 (1.22%)", "Febrile neutropenia 0/82 (0.00 %)", "Tachycardia 3/82 (3.66%)", "Atrial fibrillation 0/82 (0.00 %)", "1/82 (1.22%)", "1/82 (1.22%)", "- Attack on angina 0/82 (0.00 %)", "- Congestive heart failure 0/82 (0.00 %)", "0/82 (0.00 %)", "Adverse Events 2:", "Total: 30/89 (33.71 per cent)", "Neutropenia 5/89 (5.62%)", "Anemia 1/89 (1.12%)", "Thrombocytopenia 1/89 (1.12%)", "- Febrile neutropenia 2/89 (2.25%)", "- Tachycardia 1/89 (1.12%)", "Atrial fibrillation 1/89 (1.12%)", "- Superventricular tachycardia 0/89 (0.00 %)", "- Ventricular tachycardia 0/89 (0.00 %)", "- Attack on angina 1/89 (1.12%)", "Congestive heart failure 1/89 (1.12%)", "Atrium flutter 1/89 (1.12%)"]}